Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Sucha Sudarsanam"'
Autor:
Sucha Sudarsanam, Guohua Zhao, Dennis P. O'Malley, Jian-Feng Wang, Vladislav Chizhevsky, Yuhang Yang, Saskia Boisot, Shehla Arain, Lawrence M. Weiss
Publikováno v:
Modern Pathology
Targeting of the PD1/PD-L1 immune checkpoint pathway has rapidly gained acceptance as a therapeutic strategy for a growing number of malignancies. Testing for expression of PD-L1 in tumor cells and immune cells has been used as a companion or complem
Autor:
Virginia Burns, Sucha Sudarsanam, Cory Batenchuk, Vladislav Chizhevsky, Kim E. Zerba, Maher Albitar, Chelsea Jin
Publikováno v:
Journal of Clinical Pathology
AimsAt the time of analysis, two widely used, drug-specific, tumour-cell programmed death ligand 1 (PD-L1) assays were approved by the US Food and Drug Administration for anti-PD-1 therapies: the Dako PD-L1 immunohistochemistry (IHC) 28-8 pharmDx ass
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Autor:
Sally Agersborg, Shiping Jiang, Robert Gasparini, Christopher Mixon, Gregory Hess, Sramila Aithal, Thanh Nguyen, Sucha Sudarsanam, Lawrence M. Weiss, Maher Albitar, Forrest Blocker, Wayne Chen
Publikováno v:
Breast Cancer Research and Treatment
Purpose While HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Alternative probes ma
Autor:
Sucha Sudarsanam, Maher Albitar, Shiping Jiang, Sally Agersborg, Wanlong Ma, Vincent Funari, Wayne Chen, Forrest Blocker
Publikováno v:
Oncotarget. 9:13682-13693
// Maher Albitar 1 , Sucha Sudarsanam 1 , Wanlong Ma 1 , Shiping Jiang 1 , Wayne Chen 1 , Vincent Funari 1 , Forrest Blocker 1 and Sally Agersborg 1 1 NeoGenomics Laboratories, Aliso Viejo, CA, USA Correspondence to: Maher Albitar, email: maher.albit
Publikováno v:
Annals of Oncology. 30:xi27
Background Clinical trials show favorable OS for patients (pts) with incident aNSCLC and programmed death ligand 1 (PD-L1) expression treated with PD-L1 immune checkpoint inhibitor (ICI) pembrolizumab (PEM) or PEM-chemotherapy compared to no ICI. We
Autor:
Maher, Albitar, Sucha, Sudarsanam, Wanlong, Ma, Shiping, Jiang, Wayne, Chen, Vincent, Funari, Forrest, Blocker, Sally, Agersborg
Publikováno v:
Oncotarget
Background The role of MET amplification in lung cancer, particularly in relation to checkpoint inhibition and EGFR WT, has not been fully explored. In this study, we correlated PD-L1 expression with MET amplification and EGFR, KRAS, or TP53 mutation
Autor:
Maher Albitar, Sucha Sudarsanam, James K. McCloskey, Adam Albitar, Chirag S. Desai, Neil J. Shah, Jianhua Zhao, Jamie Koprivnikar, Catherine Lai
Publikováno v:
Blood. 132:1393-1393
Background: Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are heterogeneous groups of disorders with a spectrum of clinical presentations and outcomes. Prognosis depends on various factors including age, karyotype, performance stat
Publikováno v:
Current Drug Discovery Technologies. 9:77-80
Genome-wide RNA splicing (with gene expression) can be used to discover variations that drive specific diseases and / or change the susceptibility in individuals to drug responses including tissue specific toxicities. Evidence linking causative SNPs
Autor:
F. Racke, M. Chioda, J. Sheng, H. Hwang, K. Bloom, S. Astrow, M. Moran, J. Ramage, Sucha Sudarsanam, J. Mardekian, A.J. Iafrate
Publikováno v:
Journal of Thoracic Oncology. 13:S977
Autor:
Maher Albitar, Sally Agersborg, Wanlong Ma, Shiping Jiang, Wayne Chen, Forrest Blocker, Vincent Funari, Sucha Sudarsanam
Publikováno v:
Journal of Clinical Oncology. 36:e15604-e15604
e15604Background: Microsatellite instability (MSI) and DNA mismatch repair defect (dMMR) are dependable predictive biomarkers of colorectal cancer (CRC) response to checkpoint inhibitors. We explor...